Acusphere presses on with phase III ultrasound agent trial
This article was originally published in Clinica
Executive Summary
Acusphere has announced successful results from the pilot stage of a phase III clinical programme for its cardiovascular ultrasound-imaging (u/s) agent, AI-700. The Watertown, Massachusetts company said it now believes it has met all of the objectives of the pilot study and is on schedule to complete enrolment for the pivotal phase of the trial during the second half of 2005.